While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...

ChatGPT’s newest model has been caught leaning on Grokipedia, an AI-written encyclopedia created by Elon Musk’s xAI, to ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one of the top performers on Wednesday. Recursion extended its winning streak ...

The raise comes less than two months after Ricursive was launched by former Google LLC researchers Anna Goldie and Azalia ...

A recursive vibe journalism experiment in which Microsoft 365 Copilot's 'Prompt Coach' agent is used to wholly create an ...